ATOS

Atossa Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Quay Steven CDirector, Officer: President & CEO
$9.9k11.2k shares
BuyMay 21, 2025
$0.8797
--
Remmel H. LawrenceDirector
$7.0k10k shares
BuyMar 26, 2025
$0.70
--

News

prnewswire.comAtossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceedsprnewswire.comJun 12prnewswire.comAtossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceedsprnewswire.comJun 11prnewswire.comAtossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trialprnewswire.comMay 27prnewswire.comAtossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophyprnewswire.comMay 20seekingalpha.comAtossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcriptseekingalpha.comMay 19